Canal-U

Mon compte

Résultats de recherche

Nombre de programmes trouvés : 9742
Label UNT Conférences

le (11m50s)

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Study drug and background therapy (debates).

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : <br>Study drug and background therapy (debates).Speaker: Denise BONDS, NHLBI, USASpeaker: Michel MARRE, Paris, FRAAbstract : Study drug and background therapy (debates).L’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.Conférence enregistrée : 9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 Diabetes clinical trials : helped or hindered by the current shift in regulatory requirements? Glycaemic control is an inadequate surrogate marker of cardiovascular event reduction in patients with type 2 diabetes. Clinical trials to date have been unsuccessful ...
Voir la vidéo
Label UNT Conférences

le (15m47s)

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Non-inferiority, superiority, or both? Operationalizing the FDA guidance

Title: Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Non-inferiority, superiority, or both? Operationalizing the FDA guidanceSpeaker: Marc PFEFFER, Boston, USADiscussant: Stuart POCOCK, London, GBRRegulatory viewpoint: Kristina DUNDER, EMEA, SWEAbstract : Non-inferiority, superiority, or both? Operationalizing the FDA guidanceL’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.Conférence enregistrée : 9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 Diabetes clinical trials : helped or hindered by the current shift in regulatory requirements? Glycaemic control is an inadequate surrogate marker of cardiovascular event reduction in patients with type 2 diabetes. Clinical ...
Voir la vidéo
Label UNT Conférences

le (12m26s)

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Non-inferiority, superiority, or both? Operationalizing the FDA guidance

Title :Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Non-inferiority, superiority, or both? Operationalizing the FDA guidanceSpeaker: Marc PFEFFER, Boston, USADiscussant: Stuart POCOCK, London, GBRRegulatory viewpoint: Kristina DUNDER, EMEA, SWEAbstract : The evaluation of cardiovascular safety of rosiglitazone (2006-2010) had implications on regulatory guidance for glucose lowering drugs both in the EU and in the US and both the FDA and the CHMP guidelines for development of glucose lowering drugs have been updated including new requirements for assessment of cardiovascular safety. While the FDA Guidance is very precise specifying that the upper bound of the 95% confidence interval for the ...
Voir la vidéo
Label UNT Conférences

le (10m40s)

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Non-inferiority, superiority, or both? Operationalizing the FDA guidance (debates).

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : <br>Non-inferiority, superiority, or both? Operationalizing the FDA guidance (debates).Speaker: Marc PFEFFER, Boston, USADiscussant: Stuart POCOCK, London, GBRRegulatory viewpoint: Kristina DUNDER, EMEA, SWEAbstract : Non-inferiority, superiority, or both? Operationalizing the FDA guidance (debates).L’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.Conférence enregistrée : 9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 Diabetes clinical trials : helped or hindered by the current shift in regulatory requirements? Glycaemic control is an inadequate surrogate marker of cardiovascular event reduction in patients ...
Voir la vidéo
Label UNT Conférences

le (19m19s)

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Study drug and background therapy : on top of or vs. Metformin? The issue of background therapy and comparator

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Study drug and background therapy : on top of or vs. Metformin? The issue of background therapy and comparatorSpeaker: Michel MARRE, Paris, FRA, Ronan ROUSSEL, Paris, FRAAbstract : Study drug and background therapy : on top of or vs. Metformin? The issue of background therapy and comparatorL’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.Conférence enregistrée : 9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 Diabetes clinical trials : helped or hindered by the current shift in regulatory requirements? Glycaemic ...
Voir la vidéo
Label UNT Conférences

le (57m35s)

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : SHIfTing evidence in heart failure management.

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : SHIfTing evidence in heart failure management.Speaker: Jeffrey BORER, New York, USAAbstract : SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) involved 6505 patients with moderate to severe heart failure (HF), heart rate ?70bpm in sinus rhythm, at least one HF hospitalization during the year prior to study, and LVEF ?35% who were receiving guidelinesbased HF therapy including maximized beta blockade, who were randomized to add either placebo or ivabradine (pure HR slowing drug) during a median 22.9 months follow-up. The results of SHIFT unambiguously demonstrated the benefits of HR ...
Voir la vidéo
Label UNT Conférences

le (46m31s)

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Save life and save cost with ivabradine.

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Save life and save cost with ivabradine.Speaker: Martin COWIE, London, GBRAbstract :  Clinical evidence suggests that an elevated resting heart rate is a risk factor for mortality and morbidity in heart failure (HF) patients. SHIfT examined the effect of adding ivabradine, a heart rate lowering therapy, to optimised standard therapy in HF patients with a heart rate ?70bpm, in sinus rhythm and with left ventricular systolic dysfunction.1 Ivabradine plus standard therapy significantly reduced the risk of a primary composite event (CV death and hospitalisation for worsening HF) versus standard therapy (hazard ...
Voir la vidéo
Label UNT Conférences

le (26m40s)

Cardiovascular Clinical Trialists (CVCT) Forum – Lipid lowering agents. Now, we have an option! (SHARP, 4D, AURORA)

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Lipid lowering agents. Now, we have an option! (SHARP, 4D, AURORA)Speaker: Colin BAIGENT, Oxford, GBRAbstract : Lipid lowering agents. Now, we have an option! (SHARP, 4D, AURORA)L’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.Conférence enregistrée : 9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 Cardiovascular prevention in chronic kidney disease. New therapeutic options and future opportunities- Cardiovascular events are 10 to 20 fold higher in CKD patients. Heart failure is the main cardiovascular complication that occurs in renal patients. Nearly all ...
Voir la vidéo
Label UNT Conférences

le (20m6s)

Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients.

Title: Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients.Speakers: Chris MIX, Amgen, USA - David WHEELER, London, GBRDiscussant: Ziad MASSY, Boulogne-Billancourt, FRAAbstract : EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients.L’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.Conférence enregistrée : 9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 Cardiovascular prevention in chronic kidney disease. New therapeutic options and future opportunities- Cardiovascular events are 10 to 20 fold higher in CKD patients. Heart failure is the main cardiovascular complication that occurs ...
Voir la vidéo
Label UNT Conférences

le (10m31s)

Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients

Title : Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patientsSpeakers: Chris MIX, Amgen, USA - David WHEELER, London, GBRDiscussant: Ziad MASSY, Boulogne-Billancourt, FRAAbstract : EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients.The extracellular calcium-sensing receptor (CaR) was first described in the parathyroid gland. Recent studies have shown that the CaR is also expressed in cardiomyocytes, peri-vascular nerves of the adventitia, vascular smooth muscle cells, and endothelial cells, but our understanding of its physiological functions in the cardiovascular system remains incomplete. A variety of studies point to a possible role of CaR activity modulation ...
Voir la vidéo

 
FMSH
 
Facebook Twitter Google+
Mon Compte